Идёт набор NCT06449885

A Cohort Study in Newly Diagnosed MZL

— Наблюдательное Marginal Zone Lymphoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: patients receive optimal treatment or follow-up according to the characteristics of the disease.
Кому может быть актуально: Состояния в реестре: Marginal Zone Lymphoma. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Китай
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Prospective, Multi-center, Cohort Study in Newly Diagnosed Marginal Zone B-cell Lymphoma

Обзор

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Подробное описание

Marginal zone lymphoma (MZL) originates from the marginal zone of lymphatic follicles and can occur in the spleen, lymph nodes and mucosal lymphoid tissues, and the incidence increases with age. The clinicopathological features of each subtype of MZL are heterogeneous, and their clinical manifestations, biology, etiology, and treatment are all quite heterogeneous, and there is still significant uncertainty about the optimal treatment pathway. This prospective, multicenter, cohort study aims to describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of MZL, and to observe the therapeutic efficacy and safety of different treatment modalities.

Вмешательства

Другое patients receive optimal treatment or follow-up according to the characteristics of the disease
Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.

Первичные конечные точки

Progression-free survival [Срок оценки: assessed up to 10 years]

Вторичные конечные точки (7)

Time to treatment [Срок оценки: assessed up to 10 years]
Time to next treatment [Срок оценки: assessed up to 10 years]
ORR [Срок оценки: up to 6 months]
Overall survival [Срок оценки: assessed up to 10 years]
Adverse events [Срок оценки: Throughout the treatment period, up to 10 years]
Histologic transformation rate [Срок оценки: Throughout the study, up to 10 years]
Occurrence rate of a second tumor [Срок оценки: Throughout the study, up to 10 years]

Критерии участия

Критерии включения

Age≥ 18 years old; Male or female.
Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors).
Willing to provide biological samples required for the study, including blood samples and tumor tissue.
Voluntarily join this study and sign the informed consent form.
Willing to accept long-term follow-up.